UCP1 and Glucose intolerance: In agreement with emerging evidence regarding the UCP1-independent role of beige fat18,19,36, fat-specific CUL2–APPBP2 blockade not only improved glucose intolerance, insulin resistance and lipid profile, but also suppressed WAT inflammation and fibrosis before changes in body weight.